Announcement

Collapse
No announcement yet.

DMTs for primary progressive MS (Norwegian Perspective)

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • DMTs for primary progressive MS (Norwegian Perspective)

    Disease-modifying treatments for primary progressive multiple sclerosis (PPMS). A health technology assessment

    Publisher
    National Institute of Public Health,
    2019. On commission from
    Bestillerforum RHF.

    Authors
    Ohm IK, Tjelle TE, Rose C, Hamidi V
    Hagen G, , Fretheim, A
    Clinical experts
    Bø L, Celius EG, Holmøy T, Midgard R

    Objective
    The objective for this health technology assessment was to evaluate clinical efficacy and cost effectiveness for disease-modifying drugs for the treatment of primary progressive multiple sclerosis (PPMS).

    Key findings and conclusions
    We have systematically collected and reviewed the evidence for clinical efficacy for disease modifying treatments for PPMS.

    We included three randomised placebo-controlled trials that each compare the effect of one medication (either fingolimod, ocrelizumab or rituximab, respectively) with placebo.

    For each of the three drugs, we calculated the risk ratios for confirmed disease progression. We also report results in the form of hazard ratios. Our results show that ocrelizumab and rituximab may reduce the risk of confirmed disease progression more than placebo. In total, the results do not give us good reason to assume that one drug is better than the other.

    Fingolimod may also reduce the risk of confirmed disease progression, although to a lesser degree than for ocrelizumab and rituximab. We find these results to be less convincing than for ocrelizumab and rituximab.

    We have not conducted a full health economic evaluation as we do not have strong reasons to believe that one specific drug is better or worse than the other, and because rituximab is substantially less costly than the two other treatments.

    FULL ARTICLE (FREE PDF):
    https://www.fhi.no/contentassets/06c...-sclerosis.pdf
    Dave Bexfield
    ActiveMSers
Working...
X